LTX-109 nasal spray
Therapeutic against influenza and similar illnesses
Key Facts
About Pharma Holdings
Pharma Holdings is a clinical-stage biotech developing a novel class of direct-acting virucidal drugs for respiratory infections. Its core technology is the antimicrobial peptide LTX-109, formulated as a nasal spray, which rapidly disrupts viral envelopes. The company is targeting high-risk patient populations for influenza and COVID-like illnesses, with a lead therapeutic program advancing into Phase Ib/IIa trials in 2025. It operates with a lean, virtual model utilizing CROs and CDMOs.
View full company profileAbout Pharma Holdings
Pharma Holdings is a clinical-stage biotech developing a novel class of direct-acting virucidal drugs for respiratory infections. Its core technology is the antimicrobial peptide LTX-109, formulated as a nasal spray, which rapidly disrupts viral envelopes. The company is targeting high-risk patient populations for influenza and COVID-like illnesses, with a lead therapeutic program advancing into Phase Ib/IIa trials in 2025. It operates with a lean, virtual model utilizing CROs and CDMOs.
View full company profile